metformin
metformin: 37 clinical trials tracked.
metformin evidence translation
What we can confirm
37 tracked trials
What it means
What to watch
Prepared research question
What is verified about metformin, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence8 indications · 14 study sponsors
Related indications
Clinical Trials (37)showing 10 most recent
Metformin to Attenuate Progressive Respiratory Decline in Idiopathic Pulmonary Fibrosis (MAVRIC)
Primary endpoint: Time to death, non-elective hospitalization, or lung transplantation
Alzheimer's Disease- Systematic Multi-Arm Adaptive Randomised Trial
Primary endpoint: Change in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) score
Study on the Effect of Metformin in Improving Cardiac Function After Implantation of Left Ventricular Assist Devices
Primary endpoint: Incidence of Full Responder at 12 Months Post-LVAD Implantation
A Phase 1, Open-Label, Two-Cohort Study to Assess the Effect of a Strong CYP3A4 Inducer on the Pharmacokinetics of Atumelnant and the Effect of Atumelnant on the Pharmacokinetics of CYP3A4, P-gp, and MATE1/2-K Substrates in Healthy Participants
Primary endpoint: Cohort 1: Pharmacokinetics (AUC 0-last)
A Phase 1, Open-Label, Drug-Drug Interaction Study to Evaluate the Effect of UBT251 on the Pharmacokinetics of Single Oral Doses of Metformin, Warfarin, Atorvastatin, and Digoxin in Overweight or Obese Participants.
Primary endpoint: Area under plasma concentration-time curve of metformin (AUC0-τ) and S-warfarin, R-warfarin (AUC0-t, AUC0-∞)
A Phase 1 Study to Evaluate the Effect of Multiple Doses of ABBV-722 on the Pharmacokinetics of Cocktail Probe Substrates of CYP3A and Select Transporters in Healthy Adult Subjects
Primary endpoint: Number of Participants with Adverse Events (AEs)
The Effect of Empagliflozin and Metformin on Oxidative Capacity and Microvascular Reactivity of Skeletal Muscle in Patients With Type 2 Diabetes Mellitus
Primary endpoint: Change in skeletal muscle mitochondrial oxidative capacity
A Phase 1, Randomized, Investigator- and Participant-Blinded, Placebo-Controlled, Single- and Multiple-Ascending Dose Study to Characterize the Safety, Tolerability, and Pharmacokinetics of LY4515100 in Healthy Participants and an Open-Label Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics, Safety, and Tolerability of LY4515100 and of LY4515100 on the Pharmacokinetics of CYP and Transporter Substrates in Healthy Participants
Primary endpoint: Number of participants with one or more serious adverse event(s) (SAEs) of LY4515100 in Parts A and B
Phase 1, 2-Cohort, Open-label, Fixed-sequence, Drug-drug Interaction Study to Evaluate the Effect of Repotrectinib on the Pharmacokinetics of Transporter and CYP P450 Probe Substrates in Healthy Adult Participants
Primary endpoint: Cohort 1: Area Under the Plasma Concentration-time Curve From Time Zero to Time of Last Quantifiable Concentration of AUC (0-T) of Probe Substrate With Repotrectinib
A Phase 1, Open-Label, Fixed-Sequence Study to Evaluate the Effect of Vimseltinib on Organic Cation Transporter 2 (OCT2) Inhibition in Healthy Male Participants
Primary endpoint: Pharmacokinetic (PK): Maximum Observed Plasma Drug Concentration (Cmax) of Metformin